A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 25 Jan 2019 This trial has been completed in Spain.
- 25 Jan 2019 This trial has been discontinued in Germany.
- 21 Dec 2018 This trial was discontinued in Austria, according to European Clinical Trials Database.